报价延迟最少15分钟:2025/09/16 23:15 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.06 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.40/0.98
|
|
企业价值
48.29M
|
| 资产负债 |
|
每股账面净值
1.06
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
140.14M
|
|
每股收益
3.24
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/16 23:15 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species. |
